Education
About Us
Working with TipRanks
Follow Us
The United Laboratories International (ULIHF)
:ULIHF
RESEARCH TOOLSreports
ULIHF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.90 - $2.35
Previous CloseN/A
Volume13.00K
Average Volume (3M)3.49K
Market Cap
$2.88B
Enterprise Value$9.80B
Total Cash (Recent Filing)¥395.48M
Total Debt (Recent Filing)¥2.00B
Price to Earnings (P/E)7.0
Beta-0.41
Next Earnings
Aug 21, 2025EPS Estimate
0.18Next Dividend Ex-Date
Jul 08, 2025Dividend Yield5.52%
Share Statistics
EPS (TTM)0.20
Shares Outstanding1,817,026,500
10 Day Avg. Volume104
30 Day Avg. Volume3,491
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)N/A
Price to Sales (P/S)0.88
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.08Price Target Upside46.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
The United Laboratories International Holdings News
PremiumCompany Announcements
United Laboratories Announces HK$200 Million Share Buy-Back Plan
PremiumCompany Announcements
The United Laboratories Announces Special Dividend for 2024
PremiumCompany Announcements
United Laboratories Announces Final Dividend for 2024
PremiumCompany Announcements
United Laboratories Partners with Novo Nordisk for UBT251 DevelopmentPremiumCompany Announcements
United Laboratories’ Liraglutide Injection Gains NMPA ApprovalPremiumCompany Announcements
United Laboratories’ Eye Drops Gain Approval, Boosting Ophthalmic Portfolio
PremiumCompany Announcements
United Laboratories to Review Annual Results and Dividend Proposal
PremiumCompany Announcements
United Laboratories’ UBT251 Injection Gains FDA Approval for CKD Trials---
Bulls Say, Bears Say
Bulls Say
Cost ManagementSelling costs were reduced by Rmb260mn to Rmb715mn, showing a significant year-over-year decrease.
Growth ProjectionsFurther growth is expected from finished drugs, including the soon-to-be-approved liraglutide generic, insulins, and animal drugs.
Product LaunchesAnimal drugs are on a strong growth track with new product launches.
Bears Say
Capacity ConcernsManagement does not see extra capacity coming online to pressure 6-APA prices, which might limit future supply flexibility.
Market ExpectationsStreet's estimate has already moved up by 6% since early July, suggesting expectations may be high and challenging to exceed.
Profit Outlook1H24 net profit was in line with estimates, but only slightly above consensus, indicating limited upside surprise.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
4.72% Mutual Funds
0.09% Other Institutional Investors
91.94% Public Companies and
Individual Investors
ULIHF FAQ
What was The United Laboratories International’s price range in the past 12 months?
The United Laboratories International lowest stock price was $0.90 and its highest was $2.35 in the past 12 months.
What is The United Laboratories International’s market cap?
The United Laboratories International’s market cap is $2.88B.
When is The United Laboratories International’s upcoming earnings report date?
The United Laboratories International’s upcoming earnings report date is Aug 21, 2025 which is in 130 days.
How were The United Laboratories International’s earnings last quarter?
The United Laboratories International released its earnings results on Mar 25, 2025. The company reported $0.087 earnings per share for the quarter, missing the consensus estimate of $0.106 by -$0.019.
Is The United Laboratories International overvalued?
According to Wall Street analysts The United Laboratories International’s price is currently Undervalued.
Does The United Laboratories International pay dividends?
The United Laboratories International pays a Annually dividend of $0.038 which represents an annual dividend yield of 5.52%. See more information on The United Laboratories International dividends here
What is The United Laboratories International’s EPS estimate?
The United Laboratories International’s EPS estimate is 0.18.
How many shares outstanding does The United Laboratories International have?
The United Laboratories International has 1,817,026,500 shares outstanding.
What happened to The United Laboratories International’s price movement after its last earnings report?
The United Laboratories International reported an EPS of $0.087 in its last earnings report, missing expectations of $0.106. Following the earnings report the stock price went down -10.638%.
Which hedge fund is a major shareholder of The United Laboratories International?
Currently, no hedge funds are holding shares in ULIHF
---
The United Laboratories International Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.08 (46.48% Upside)
$2.08 (46.48% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.00%
12-Months-Change
Fundamentals
Return on Equity
19.62%
Trailing 12-Months
Asset Growth
19.43%
Trailing 12-Months
Company Description
The United Laboratories International
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
---
ULIHF Stock 12 Month Forecast
Average Price Target
$2.08
▲(46.48% Upside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Huazhu Group Ltd
―
Best Analysts Covering ULIHF
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-19.70%
reiterated a buy rating 17 days ago
Copying David Shang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.70% per trade.
---